Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.
Mannucci
P M
PM
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Luigi Villa Foundation, Department of Medicine, University of Milan, Milan, Italy. piermannuccio.mannucci@unimi.it
Spreafico
M
M
Peyvandi
F
F
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics*; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases